Literature DB >> 15507223

Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats.

Robert Adamec1, Gerd D Bartoszyk, Paul Burton.   

Abstract

We examined the effect of Vilazodone, a selective serotonin reuptake inhibitor (SSRI) and serotonin 1A (5-HT(1A)) receptor agonist [Bartoszyk, G.D., Hegenbart, R., Ziegler, H., 1997. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur. J. Pharmacol. 322, 147-153.], on change in affect following predator stress. Vilazodone and vehicle injection (intraperitoneal) occurred either 10 min after predator stress (prophylactic testing), or 90 min prior to behavioral testing for the effects of predator stress (therapeutic testing). Predator stress involved unprotected exposure of rats to a domestic cat. Behavioral effects of stress were evaluated with hole board, plus-maze, and acoustic startle tests 1 week after stress. Predator stress increased anxiety-like behavior in the plus-maze and elevated response to acoustic startle. In prophylactic testing, Vilazodone affected stress potentiation of startle at doses above 5 mg/kg. Vilazodone increased stress elevation of startle at 10 mg/kg. Higher doses of Vilazodone (20 and 40 mg/kg) blocked stress potentiation of startle. In contrast, Vilazodone had no effect on stress potentiation of anxiety in the plus-maze. In therapeutic testing, Vilazodone increased stress elevation of startle at all doses. In contrast, therapeutic Vilazodone had no effect on stress potentiation of anxiety in the plus-maze. Taken together, the data suggest a prophylactic potential for Vilazodone in the treatment of changes in hypervigilance following severe stress.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507223     DOI: 10.1016/j.ejphar.2004.09.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

Review 1.  Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Authors:  Lee A Dawson; Jeannette M Watson
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

2.  Social defeat stress produces prolonged alterations in acoustic startle and body weight gain in male Long Evans rats.

Authors:  John V K Pulliam; Ahmad M Dawaghreh; Ernest Alema-Mensah; Paul M Plotsky
Journal:  J Psychiatr Res       Date:  2009-07-01       Impact factor: 4.791

3.  CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD.

Authors:  Robert Adamec; Dennis Fougere; Victoria Risbrough
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-15       Impact factor: 5.176

Review 4.  Targeting memory processes with drugs to prevent or cure PTSD.

Authors:  Christopher K Cain; George D Maynard; John H Kehne
Journal:  Expert Opin Investig Drugs       Date:  2012-07-27       Impact factor: 6.206

5.  Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor.

Authors:  Thomas L Schwartz; Umar A Siddiqui; Stephen M Stahl
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

6.  The auditory startle response in post-traumatic stress disorder.

Authors:  S E Siegelaar; M Olff; L J Bour; D Veelo; A H Zwinderman; G van Bruggen; G J de Vries; S Raabe; C Cupido; J H T M Koelman; M A J Tijssen
Journal:  Exp Brain Res       Date:  2006-03-09       Impact factor: 1.972

Review 7.  Vulnerability to lasting anxiogenic effects of brief exposure to predator stimuli: sex, serotonin and other factors-relevance to PTSD.

Authors:  Robert Adamec; Andrew Holmes; Jacqueline Blundell
Journal:  Neurosci Biobehav Rev       Date:  2008-05-13       Impact factor: 8.989

8.  Translatability scoring in drug development: eight case studies.

Authors:  Alexandra Wendler; Martin Wehling
Journal:  J Transl Med       Date:  2012-03-07       Impact factor: 5.531

9.  Predicting impaired extinction of traumatic memory and elevated startle.

Authors:  Rebecca Nalloor; Kristopher Bunting; Almira Vazdarjanova
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

10.  Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use.

Authors:  Mandeep Singh; Thomas L Schwartz
Journal:  Neuropsychiatr Dis Treat       Date:  2012-03-23       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.